Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors
Key Highlights
- ➤Aardvark appoints David Zhang, Ph.D., MBA, as independent director effective October 7, 2026
- ➤Zhang brings more than 25 years of clinical strategy, biostatistics and regulatory experience
- ➤Zhang says ARD-101 faces important regulatory and development decisions for Prader-Willi Syndrome
- ➤Aardvark discloses an FDA clinical hold on ARD-101 and ongoing FDA engagement
Expert Statements
Tien Lee, Founder and Chief Executive Officer of Aardvark Therapeutics
“David has spent more than 25 years designing clinical programs, analyzing pivotal trial data and supporting regulatory submissions, including the Phase 3 study design, readout and New Drug Application for CAMZYOS® (mavacamten) at MyoKardia. His experience and strategic perspective will be a valuable addition to our Board at an important time for Aardvark. We are pleased to welcome him.”
David Zhang, Independent director of Aardvark Therapeutics
“Aardvark is at a pivotal moment, with important decisions ahead for ARD-101. I look forward to working with Tien and the Board to help navigate the regulatory landscape and shape the next phase of development for people living with Prader-Willi Syndrome.”
Brings more than 25 years of experience in clinical strategy, biostatistics and regulatory submissions from Abivax, Alumis, MyoKardia and Genentech/Roche
SAN DIEGO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced the appointment of David Zhang, Ph.D., MBA, to its Board of Directors, effective October 7, 2026. Dr. Zhang will serve as an independent director.
Get started
Create a free account to read the full story.